Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

Go­ing block­buster hunt­ing, Vas Narasimhan out­lines vi­sion for ‘pure-play’ No­var­tis

By the time 2023 is over, No­var­tis ex­pects to be mov­ing much lighter: It will have spun out its gener­ics sub­sidiary San­doz, com­plet­ed lay­offs of thou­sands of staffers world­wide and put in new in­ter­nal struc­tures for run­ning the com­pa­ny.

And it will be ready to hunt for block­busters.

CEO Vas Narasimhan un­der­scored No­var­tis’ up­com­ing trans­for­ma­tion in­to a “pure-play” com­pa­ny, re­it­er­at­ing across a se­ries of calls — one with re­porters, two with in­vestors and an­a­lysts — that the new struc­ture would boost its R&D pro­duc­tiv­i­ty and sharp­en its fo­cus on big, new med­i­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.